This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.
Study Type
OBSERVATIONAL
Enrollment
98
Observe dose changes of Tyvaso over time
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Regents of the University of California
La Jolla, California, United States
UCLA Medical Center
Los Angeles, California, United States
Southern California Permanente
Pasadena, California, United States
Central Coast Chest Consultants
San Luis Obispo, California, United States
Pacific Sleep Disorders Center
Stockton, California, United States
Prime Healthcare, PC
West Hartford, Connecticut, United States
Bay Area Cardiology Associates, PA
Brandon, Florida, United States
Florida Lung & Sleep Specialist
Celebration, Florida, United States
Unnamed facility
Jacksonville, Florida, United States
Sacred Heart Medical Group
Miramar Beach, Florida, United States
...and 42 more locations